High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
--
--
-0.503
-24.88%
--
--
-0.530
-62.41%
Estimates Revision
The market is revising Downward the revenue expectations for Senti Biosciences, Inc. (SNTI) for FY2025, with the revenue forecasts being adjusted by -25% over the past three months. During the same period, the stock price has changed by 59.71%.
Revenue Estimates for FY2025
Revise Downward
-25%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+6.41%
In Past 3 Month
Stock Price
Go Up
+59.71%
In Past 3 Month
3 Analyst Rating
Wall Street analysts forecast SNTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNTI is 10.00 USD with a low forecast of 6.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.220
Low
6.00
Averages
10.00
High
12.00
Current: 2.220
Low
6.00
Averages
10.00
High
12.00
Leerink
Jeffrey La Rosa
Outperform
initiated
$6
2025-11-21
Reason
Leerink
Jeffrey La Rosa
Price Target
$6
2025-11-21
initiated
Outperform
Reason
Leerink analyst Jeffrey La Rosa initiated coverage of Senti Bio with an Outperform rating and $6 price target. The firm believes Senti's novel LogicGated gene circuit platform offers a promising solution to solve the therapeutic window problem that has plagued cell therapies pursuing cancers with "dirty" antigen targets. The company's lead clinical candidate, SENTI-202, is an elegantly designed allogeneic, or off-the-shelf, CAR-NK cell therapy in Phase 1 for relapsed or refractory acute myeloid leukemia. For Leerink, the preliminary Phase 1 dose escalation data reported to date help validate SENTI-202's Logic-Gated design and support a potentially differentiated clinical profile relative to currently available AML therapies and the industry's past attempts at developing immune cell-based therapies for the indication.
H.C. Wainwright
initiated
$12
2025-10-14
Reason
H.C. Wainwright
Price Target
$12
2025-10-14
initiated
Reason
H.C. Wainwright initiated coverage of Senti Bio with a Buy rating and $12 price target. The firm believes the company's allogeneic CAR-NK cell therapy platform has the potential to treat several cancer types including hematologic malignancies and solid tumors. It views Senti as an "underappreciated CAR-NK player with a differentiated platform with a near-term catalyst" in Q4.
Laidlaw
NULL -> Buy
initiated
$5
2025-06-06
Reason
Laidlaw
Price Target
$5
2025-06-06
initiated
NULL -> Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Senti Biosciences Inc (SNTI.O) is -1.34, compared to its 5-year average forward P/E of -1.11. For a more detailed relative valuation and DCF analysis to assess Senti Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.11
Current PE
-1.34
Overvalued PE
0.30
Undervalued PE
-2.53
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.74
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.98
Undervalued EV/EBITDA
-2.47
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
18.97
Current PS
0.00
Overvalued PS
44.03
Undervalued PS
-6.09
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
SNTI News & Events
Events Timeline
(ET)
2025-11-13
17:00:07
Senti Bio Announces Q3 Earnings Per Share of 69 Cents, Exceeding Consensus Estimate of 57 Cents
2025-08-12 (ET)
2025-08-12
09:16:33
Senti Bio releases virtual "What This Means" segment
2025-08-07 (ET)
2025-08-07
08:10:47
Senti Bio reports Q2 EPS (56c) vs. ($2.45) last year
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/1cf0298b698d197fdec9aca902aedb074b6ff9a4ca9744f66593e70725b73a12.jpg)
Preview
8.5
11-17NASDAQ.COMRepare Surges 30%, Nuvalent Rises 9% in After-Hours Biotech Gains
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
1.0
10-16NewsfilterSenti Bio to Showcase at Chardan's 9th Annual Genetic Medicines Conference
Preview
1.0
09-18NewsfilterSenti Bio to Showcase at the MedInvest Biotech & Pharma Conference
Sign Up For More News
People Also Watch
FAQ
What is Senti Biosciences Inc (SNTI) stock price today?
What is Senti Biosciences Inc (SNTI)'s business?
What is the price predicton of SNTI Stock?
What is Senti Biosciences Inc (SNTI)'s revenue for the last quarter?
What is Senti Biosciences Inc (SNTI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Senti Biosciences Inc (SNTI)'s fundamentals?
How many employees does Senti Biosciences Inc (SNTI). have?